These trials completed more than 12 months ago and should have reported results.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Exempt 2007-003211-31 ENSAYO CLÍNICO DE FASE I-II, NO ALEATORIZADO, MULTICENTRICO PARA EVALUAR LA SEGURIDAD Y LA EFICACIA DE LA COMBINACIÓN DE SORAFENIB (BAY 43-9006), GEMCITABINA Y RADIOTERAPIA CONCURRENTE EN EL TRATAMIE... not-yet-due
Ongoing 2008-004223-27 Estudio fase II, de la combinación de Oxaliplatino y Sorafenib en pacientes con Adenocarcinoma gástrico o de la unión gastroesofágica localmente avanzado o metastásico, en progresión tras un esquema ... not-yet-due
Ongoing 2009-010417-73 Estudio abierto, no aleatorizado, multicéntrico, en fase II, para evaluar la eficacia y seguridad de Bevacizumab en combinación con Capecitabina y Oxaliplatino, como primera línea de tratamiento en pa... not-yet-due
Completed, but no date 2009-017331-18 Estudio abierto de fase II para evaluar los posibles marcadores tumorales predictivos en pacientes con cáncer colorrectal metastásico y tumor con KRAS no mutado tratados con FOLFOX6m y panitumumab com... bad-data
Completed, but no date, and reported results 2010-018430-48 Estudio de fase II para evaluar la eficacia y la seguridad de la quimiorradioterapia con 5-fluorouracilo, mitomicina C y panitumumab como tratamiento del carcinoma anal de células escamosas bad-data
Completed, but no date 2010-019236-12 Ensayo clínico fase II de un solo brazo, multicéntrico y prospectivo para la validación de biomarcadores en pacientes con cáncer colorrectal avanzado y/o metastásico con gen KRAS no mutado tratados co... bad-data
Ongoing 2010-021738-72 Estudio fase II abierto, no aleatorizado, para evaluar la eficacia y seguridad del tratamiento neoadyuvante concomitante de Gemcitabina y Erlotinib seguido de Gemcitabina, Erlotinib y radioterapia en ... not-yet-due
Ongoing, reported early 2011-000143-24 Phase IV, multicentric study to evaluate correlation between global objectives response according RECIST v1.1 criteria evaluated by conventional images tecniques with morfologic response by TAC and pa... not-yet-due
Completed, report not yet due 2014-002063-14 Induction FOLFOX with or without Aflibercept followed by chemoradiation in High Risk Locally Advanced Rectal Cancer. Phase II randomized, multicenter, open label trial 2020-02-04 not-yet-due
Ongoing 2016-002333-29 Preoperative induction therapy with 12 weeks of Panitumumab in combination with mFOLFOX-6 in an enriched population (Quadruple Wild-Type) of patients with mrT3 rectal cancer of the middle third with c... not-yet-due
Exempt 2016-003838-24 A single arm Phase I-II multicenter trial with avelumab plus autologous dendritic cell vaccine in pre-treated mismatch repair-proficient (MSS) metastatic colorectal cancer patients. not-yet-due
Ongoing 2017-001639-38 A phase II trial to evaluate the efficacy and safety of FOLFIRI + panitumumab as first-line treatment in elderly patients with RAS/BRAF wild-type unresectable metastatic colorectal cancer and good per... not-yet-due
Ongoing 2017-004519-38 Randomized phase II study to evaluate the efficacy of second-line FOLFIRI + panitumumab in subjects with wild type RAS metastatic colorectal cancer who have received FOLFOX + panitumumab in first-line... not-yet-due
Ongoing 2018-004835-56 Phase II study of Durvalumab (MEDI4736) plus Total Neoadjuvant Therapy (TNT) in locally advanced rectal cancer not-yet-due